What is Aprea Therapeutics Operating Cash Flow per Share?
Aprea Therapeutics's operating cash flow per share for the
three
months ended in Mar. 2025 was $-0.61.
Aprea Therapeutics's operating cash flow per share for the trailing twelve months (TTM) ended in Mar. 2025 was $-2.22.
During the past 3 years, the average Operating Cash Flow per Share Growth Rate was 58.90% per year.
During the past 5 years, the average Operating Cash Flow per Share Growth Rate was 52.70% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the OCF Growth Rate using Operating Cash Flow per Share data.
The historical rank and industry rank for Aprea Therapeutics's Operating Cash Flow per Share or its related term are showing as below:
APRE'
s 3-Year OCF Growth Rate Range Over the Past 10 Years
Min: -25.7 Med: 44.7 Max: 58.9
Current: 58.9
During the past 8 years, Aprea Therapeutics's highest 3-Year average Operating Cash Flow per Share Growth Rate was 58.90% per year. The lowest was -25.70% per year. And the median was 44.70% per year.
APRE's 3-Year OCF Growth Rate is ranked better than 92.36% of 1217
companies
in the Biotechnology industry
Industry Median: 9.3
vs APRE: 58.90
Aprea Therapeutics Operating Cash Flow per Share Historical Data
The historical data trend for Aprea Therapeutics's Operating Cash Flow per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Aprea Therapeutics Operating Cash Flow per Share Chart
Competitive Comparison of Aprea Therapeutics's Operating Cash Flow per Share
For the Biotechnology subindustry, Aprea Therapeutics's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aprea Therapeutics's Price-to-Operating-Cash-Flow Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Aprea Therapeutics's Price-to-Operating-Cash-Flow distribution charts can be found below:
* The bar in red indicates where Aprea Therapeutics's Price-to-Operating-Cash-Flow falls into.
Operating Cash Flow per Share for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.22
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aprea Therapeutics Operating Cash Flow per Share Related Terms
Thank you for viewing the detailed overview of Aprea Therapeutics's Operating Cash Flow per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline products include ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
APRE has been successfully added to your 